Interleukin 33 in Juvenile Idiopathic Arthritis Patients
NCT ID: NCT03835624
Last Updated: 2019-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2019-02-12
2019-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects:This study will be a case-control study including sixty children with juvenile idiopathic arthritis attending pediatric rheumatology clinic of Benha University Hospital and Benha children hospital and thirty apparently healthy children as controls. They will be classified into:
* Group (I) study group:60 cases of children with juvenile idiopathic arthritis.
* Group (II) Control group:60 of apparently healthy children matched for age and sex
A)Full history taking
B) Full clinical examination
C) Clinical assessment of disease activity
D) Laboratory Investigations:
All subjects will be investigated by
1. complete blood count.
2. Erythrocyte sedmentation rate.
3. C-reactive protein .
4. Liver enzymes: ALT and AST.
5. Rheumatoid factor.
6. Antinuclear antibody (ANA).
7. serum ferritin
8. serum and synovial fluid Interleukin 33 by ELISA and its relative expression in peripheral blood mononuclear cells by PCR
E) Musculoskeletal Ultrasound examination
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
juvenile idiopathic arthritis
about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
interleukin 33
serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
control group
about 60 apparently healthy children with comparable age and sex to the patients.
serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples.
interleukin 33
serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
interleukin 33
serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1. Other autoimmune diseases Vasculitis- SLE- Rheumatic fever- Dermatomyositis- Polymyositis- Enteropathic arthritis- Behcet disease- Sjogren-Scleroderma- Mixed connective diseases
2. Infectious disease or septic arthritis.
3. Metabolic diseases.
4. Endocrine diseases.
5. Neuropathic diseases.
6. Heritable bone disease.
7. Neoplastic diseases including leukemia.
8. Sarcoidosis.
9. Familial Mediterranean fever. 2-Exclusion of children with diseases that affect serum level of IL 33 as:
<!-- -->
1. Inflammatory diseases of airway e.g asthma
2. Inflammatory bowel disease
3. Systemic lupus erythmatosus
4. Inflammatory skin disease e.g :atopic dermatitis
5. Cancer
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Waleed Ahmed Salaheldeen Hassan
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Waleed Hassan, MD
Role: PRINCIPAL_INVESTIGATOR
Benha university- Qaluibya- Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha University Hospital
Banhā, Qalyubia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Benha University
Identifier Type: -
Identifier Source: org_study_id